Free Trial
→ Goldman Sachs just told you what to buy (most people missed it) (From Behind the Markets) (Ad)tc pixel
NASDAQ:APRE

Aprea Therapeutics Q4 2025 Earnings Report

Aprea Therapeutics logo
$0.76 -0.01 (-0.81%)
Closing price 03:58 PM Eastern
Extended Trading
$0.74 -0.02 (-2.51%)
As of 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Aprea Therapeutics EPS Results

Actual EPS
-$0.32
Consensus EPS
-$0.38
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Aprea Therapeutics Revenue Results

Actual Revenue
$0.00 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aprea Therapeutics Announcement Details

Quarter
Q4 2025
Date
3/16/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Aprea Therapeutics' Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Aprea Therapeutics' Q4 2025 Press ReleasePress Release
(8-K)
Aprea Therapeutics' Q4 2025 Annual reportAnnual report
(10-K)

Aprea Therapeutics Earnings Headlines

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid ...
June 1 at 5:13 PM  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/aprea-therapeutics-presents-updated-phase-120000389.html
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
June 1 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304318/0/en/aprea-therapeutics-presents-updated-phase-1-data-on-wee1-inhibitor-apr-1051-at-asco-2026-demonstrating-early-monotherapy-activity-and-manageable-tolerability-in-advanced-solid-tumo.html
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
June 3 at 1:00 AM  |  Brownstone Research (Ad)
Aprea Therapeutics Closes Oversubscribed $30 Million Private Placement to Advance APR-1051 Development and Reports Positive Early Data from Phase 1 Trial
May 13, 2026  |  quiverquant.comQ
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/13/3293807/0/en/aprea-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update.html
Oppenheimer initiates coverage of Aprea Therapeutics (APRE) with outperform recommendation
May 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/oppenheimer-initiates-coverage-of-aprea-therapeutics-apre-with-outperform-recommendation/ar-AA22ERPz
See More Aprea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email.

About Aprea Therapeutics

Aprea Therapeutics (NASDAQ:APRE) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS. In addition to its lead program, Aprea maintains a pipeline of early‐stage candidates and explores combination regimens intended to enhance response rates and overcome resistance mechanisms associated with TP53 dysfunction.

Aprea conducts global clinical development activities, collaborating with academic centers and biopharmaceutical partners in North America and Europe. These partnerships support Aprea’s efforts to accelerate trial enrollment, broaden access to investigational therapies and facilitate regulatory interactions across multiple jurisdictions.

Founded in 2013 and headquartered in San Francisco, California, Aprea is led by a management team with extensive experience in oncology drug development. The company’s scientific leadership combines expertise in molecular biology, translational research and clinical operations to advance its precision oncology approach for patients with high‐unmet‐need cancers.

View Aprea Therapeutics Profile
Earnings Tools